Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPC5 | Q9UL62 | 19/20 | 0.79 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17501655 | 0.96 | TRPC5 (0.79) | TRPC5ALDH1A1NPSR1 | |
| SCHEMBL17517353 | 0.91 | TRPC5 (0.65) | TRPC5 | |
| SCHEMBL17501657 | 0.90 | TRPC5 (0.64) | TRPC5 | |
| SCHEMBL17501674 | 0.88 | TRPC5 (1.00) | TRPC5 | |
| SCHEMBL17501679 | 0.86 | TRPC5 (1.00) | TRPC5 | |
| SCHEMBL17501671 | 0.83 | TRPC5 (0.76) | TRPC5ALDH1A1NPSR1 | |
| SCHEMBL17501661 | 0.82 | TRPC5 (0.66) | TRPC5 | |
| SCHEMBL20752041 | 0.82 | TRPC5 (0.81) | TRPC5 | |
| SCHEMBL20752030 | 0.82 | TRPC5 (0.53) | TRPC5ALDH1A1NPSR1 | |
| SCHEMBL17522767 | 0.79 | TRPC5 (0.83) | TRPC5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220031706-A1 | TRPC ION CHANNEL INHIBITORS FOR USE IN THERAPY | UNIVERSITY OF LEEDS (GB) | 2022-02-03 | — | — | US | disclosed |
| EP-3180318-B1 | QUINAZOLINE-2,4(1H,3H)-DIONE DERIVATIVES AS TRCP5 MODULATORS FOR THE TREATMENT OF NEUROPSYCHIATRIC DISORDERS | HYDRA BIOSCIENCES INC (US) | 2019-02-20 | — | — | EP | disclosed |
| EP-3180318-B1 | QUINAZOLINE-2,4(1H,3H)-DIONE DERIVATIVES AS TRCP5 MODULATORS FOR THE TREATMENT OF NEUROPSYCHIATRIC DISORDERS | HYDRA BIOSCIENCES INC (US) | 2019-02-20 | — | — | EP | disclosed |
| US-9745272-B2 | Quinazoline-2,4(1 H,3H)-dione derivatives | HYDRA BIOSCIENCES, INC. (US) | 2017-08-29 | — | — | US | disclosed |
| US-9745272-B2 | Quinazoline-2,4(1 H,3H)-dione derivatives | HYDRA BIOSCIENCES, INC. (US) | 2017-08-29 | — | — | US | disclosed |
| US-9745272-B2 | Quinazoline-2,4(1 H,3H)-dione derivatives | HYDRA BIOSCIENCES, INC. (US) | 2017-08-29 | — | — | US | disclosed |
| EP-3180318-A1 | QUINAZOLINE-2,4(1H,3H)-DIONE DERIVATIVES AS TRCP5 MODULATORS FOR THE TREATMENT OF NEUROPSYCHIATRY DISORDERS | Hydra Biosciences, Inc. (US) | 2017-06-21 | — | — | EP | disclosed |
| WO-2016023826-A1 | QUINAZOLINE-2,4(1H,3H)-DIONE DERIVATIVES AS TRCP5 MODULATORS FOR THE TREATMENT OF NEUROPSYCHIATRY DISORDERS | HYDRA BIOSCIENCES, INC. (US) | 2016-02-18 | — | — | WO | disclosed |
| WO-2016023826-A1 | QUINAZOLINE-2,4(1H,3H)-DIONE DERIVATIVES AS TRCP5 MODULATORS FOR THE TREATMENT OF NEUROPSYCHIATRY DISORDERS | HYDRA BIOSCIENCES, INC. (US) | 2016-02-18 | — | — | WO | disclosed |
| US-20160039772-A1 | QUINAZOLINE-2,4(1H,3H)-DIONE DERIVATIVES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-02-11 | — | — | US | disclosed |
| US-20160039772-A1 | QUINAZOLINE-2,4(1H,3H)-DIONE DERIVATIVES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-02-11 | — | — | US | disclosed |
| US-20160039772-A1 | QUINAZOLINE-2,4(1H,3H)-DIONE DERIVATIVES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160039772-A1 | QUINAZOLINE-2,4(1H,3H)-DIONE DERIVATIVES | TRPC5, HTR5A, TRPV5 | TRPC5 1/4885ALDH1A1 1768/4885NPSR1 56/4885 |
| US-20220031706-A1 | TRPC ION CHANNEL INHIBITORS FOR USE IN THERAPY | TRPC1, TRPC7, TRPC4 | TRPC5 6/4885ALDH1A1 2054/4885NPSR1 289/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.